Ipatasertib Explained

Iupac Name:	(S)-2-(4-Chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[''d'']pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
Routes Of Administration:	PO
Cas Number:	1001264-89-6
Unii:	524Y3IB4HQ
Atc Prefix:	None
Kegg:	D10641
Chemspiderid:	28189084
C:	24
H:	32
Cl:	1
N:	5
O:	2
Smiles:	CC(C)NC[C@@H](C(=O)N1CCN(CC1)C1=C2[C@H](C)C[C@@H](O)C2=NC=N1)C1=CC=C(Cl)C=C1
Stdinchi:	1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1
Stdinchikey:	GRZXWCHAXNAUHY-NSISKUIASA-N

Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of AKT, which is a key component of the PI3K/AKT pathway. Ipatasertib was discovered by Genentech in collaboration with Array Biopharma and is currently in phase III trials for treatment of breast cancer.

In vitro, ipatasertib showed activity against all three isoforms of Akt.^[1]

Notes and References

1. Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, Savage H, Guan Z, Hong R, Kassees R, Lee LB, Risom T, Gross S, Liederer BM, Koeppen H, Skelton NJ, Wallin JJ, Belvin M, Punnoose E, Friedman LS, Lin K . 6 . Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models . Clinical Cancer Research . 19 . 7 . 1760–72 . April 2013 . 23287563 . 10.1158/1078-0432.CCR-12-3072 . free .